In Phase II Clinical Trials
Development of Effective and Innovative Medicines to Address the needs of Patients and Improve their Health, Longevity and Quality of Life.
Message: Mr Lee Share Purchase
Generic_profile
Rank: [?]
Mail Room
Points: [?]
165
Rating: [?]
Votes: 1 Score: 3.0
  • Currently 3.0/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Fact Sheet

in response to Mr Lee Share Purchase by akshaya02
posted on Feb 05, 08 10:04PM

Hi Agoracom;

According to the fact sheet, products ARX 212, 828, and 838 are listed as part of being part of robust pipeline, however, the fact sheet also states these products are not currently under development. I am confused as according to prior press releases at least 828 and 838 were under development. It would be nice for the company to provide a clear update on the status of the products. Is the company not working on these products because they did not work out or it is waiting for something. If they did not work out why are they listed on the fact sheet as being part of the robust pipeline?

Please ask the company to provide an update on the status of research activities.

New Message

Please login to post a reply

Executive Address
Alrxsmall
Michael Lee
President
May 18, 2006

 

Michael Lee provides the investor community an update on recent events

View Broadcast

Stock Quote